Trial Profile
Defining the role of endogenous glucagon-like peptide-1 (GLP-1) in the glycaemic, triglyceride and energy expenditure responses to fat in patients with Type 2 Diabetes (T2D) using Galvus (vildagliptin) and the GLP-1 receptor antagonist exendin (9-39)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2020
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Avexitide
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 08 Jul 2016 Planned End Date changed from 12 Dec 2016 to 31 Jul 2018.
- 08 Jul 2016 Status changed from not yet recruiting to recruiting.